Table 1.
Clinical and pathological results of patients in the groups
| Group 1 (n = 29) HR-HPV(−) CIN 0 |
Group 2 (n = 21) HR-HPV(+) CIN 0 |
Group 3 (n = 20) HR-HPV(+) CIN1 |
Group 4 (n = 24) HR-HPV(+) CIN2–3 |
P value | |
|---|---|---|---|---|---|
| Age (year), mean ± SD | 44.3 ± 10.6 | 42.2 ± 12.4 | 42.7 ± 10.3 | 39.1 ± 7.6 | 0.1698* |
| Parity, n (min-max) | 1 (0–4) | 2 (0–6) | 1 (1–5) | 2 (0–5) | 0.1245# |
| Initial pap test results | |||||
| ASCUS | 22 | 7 | 4 | 1 | < 0.0001# |
| L-SIL | 7 | 9 | 11 | 5 | |
| H-SIL or ASC-H | – | 5 | 5 | 18 | |
| HR-HPV types | |||||
| 16 | – | 9 | 4 | 3 | |
| 18 | – | 8 | 8 | 5 | < 0.0001# |
| Other | – | 0 | 5 | 5 | |
| Multiple | – | 4 | 3 | 11 | |
| Ki-67, median (min-max) | 25 (5–60) | 29 (0–85) | 24 (5–100) | 82 (30–100) | < 0.0001$ |
| p16, median (min-max) | 25 (0–80) | 34 (0–51.5) | 20 (0–66) | 67,5 (15–100) | 0.0025$ |
| Number of immune cells | 27.9 ± 6.7 | 33.5 ± 6.2 | 34.1 ± 5.8 | 36.3 ± 6.9 | 0.4190* |
| Leep or Conization rate, n (%) | 0 | 1/21 | 8/20 | 24/24 | < 0.0001# |
| HPV persistence | – | 2 | 3 | 4 | 0.0296# |
| CIN persistence or recurrence | – | 1 | 0 | 3 | 0.0581# |
*ANOVA, #Chi-Squared, $Kruskal Wallis test
Ki-67 expression: Goup IV different from group I, II, III. No differences between group I, II, III
p16 expression: Group IV different from group I, II, III. No differences between group I, II, III